Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | DHPS | P49366 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241086 | 0.88 | PSMB1 (0.48) | MAPK14MEN1KMT2AACHEEGLN1 | |
| SCHEMBL13392342 | 0.88 | PSMB1 (0.48) | MAPK14MEN1KMT2AACHEEGLN1 | |
| SCHEMBL582811 | 0.86 | HSP90AB1 (0.61) | HSP90AB1ACHEALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL29779010 | 0.85 | PLAU (0.47) | MAPK14HSP90AB1KMT2AEGLN1ROCK2 | |
| SCHEMBL29136066 | 0.85 | PLAU (0.47) | MAPK14HSP90AB1KMT2AEGLN1ROCK2 | |
| SCHEMBL2422376 | 0.85 | ALDH1A1 (0.46) | EGLN1ALDH1A1 | |
| SCHEMBL29136019 | 0.85 | KMT2A (0.45) | KMT2AEGLN1ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL30656512 | 0.85 | KMT2A (0.45) | KMT2AEGLN1ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL582560 | 0.83 | HSP90AB1 (0.53) | HSP90AB1ACHEALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL1571627 | 0.82 | MAPT (0.52) | ROCK2ROCK1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802064-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2416660-B1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20130345173-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8546564-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC. | 2012-04-19 | — | — | US | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| US-5350761-A | Lipoxygenase inhibitors as antiinflammatory agents and antiallergens | CIBA-GEIGY CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| US-5334600-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345173-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, FFAR3 | MAPK14 4756/4885HSP90AB1 2269/4885MEN1 2773/4885 |
| US-20120094957-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, FFAR3 | MAPK14 4768/4885HSP90AB1 2735/4885MEN1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.